Cited by 1713D Printing in Biomedical ResearchTissue Engineering and Regenerative MedicineCellular Mechanics and Interactions

Biomimetic 3D tissue models for advanced high-throughput drug screening

Open access
Nam, Ki-Hwan, Smith, Alec S.T., Lone, Saifullah, Kwon, Sunghoon, Kim, Deok-Ho·2015·SLAS Technology

Abstract

Most current drug screening assays used to identify new drug candidates are 2D cell-based systems, even though such in vitro assays do not adequately re-create the in vivo complexity of 3D tissues. Inadequate representation of the human tissue environment during a preclinical test can result in inaccurate predictions of compound effects on overall tissue functionality. Screening for compound efficacy by focusing on a single pathway or protein target, coupled with difficulties in maintaining long-term 2D monolayers, can serve to exacerbate these issues when using such simplistic model systems for physiological drug screening applications. Numerous studies have shown that cell responses to drugs in 3D culture are improved from those in 2D, with respect to modeling in vivo tissue functionality, which highlights the advantages of using 3D-based models for preclinical drug screens. In this review, we discuss the development of microengineered 3D tissue models that accurately mimic the physiological properties of native tissue samples and highlight the advantages of using such 3D microtissue models over conventional cell-based assays for future drug screening applications. We also discuss biomimetic 3D environments, based on engineered tissues as potential preclinical models for the development of more predictive drug screening assays for specific disease models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2211068214557813

Cites

123 of 123 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 3D tissue models, such as in vitro tissue-engineered disease models, have shown promise for overcoming obstacles faced with 2D cultured cells and animal models.

    “3D tissue models, such as in vitro tissue-engineered disease models have shown promise for addressing the current obstacles faced with 2D in vitro cultured cells and animal models [352–356].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 2

  1. [91]Lee WJ Liver tissue engineering based on poly (ethylene glycol) hydrogels. Dissertation 2010 Standford University
  2. [116]Juhas M Engelmayr GC Fontanella AN Palmer GM Bursac N Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vino. PNAS 2014 111 5508 5513 24706792 PMC3992675

Cited by

Sorted by citations

Authors
Nam, K.-H., Smith, A. S. T., Lone, S., Kwon, S., & Kim, D.-H.
Affiliations
  • Seoul National University (KR)
  • University of Washington (US)
Corresponding author
Kim, Deok-Ho
Venue
SLAS Technology
Publisher
Elsevier BV
Published
2015-06
Volume
20
Issue
3
Pages
201-215
ISSN
2472-6303 (ISSN-L)
OpenAlex
W1989662123
Cited by
171
References
123
Citations by year
2026: 9 · 2025: 14 · 2024: 10 · 2023: 13 · 2022: 13 · 2021: 13 · 2020: 11 · 2019: 18 · 2018: 25 · 2017: 16 · 2016: 20 · 2015: 9
FWCI
1.29
Type
journal article
Language
en
Open access
Locations
  • SLAS TECHNOLOGY (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Heart Association (13SDG14560076)
  • Muscular Dystrophy Association (MDA 255907, 255907)
  • Washington State University
  • University of Washington
  • Korea Basic Science Institute (D34500)
  • Institute for Basic Science
  • National Institutes of Health
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR064395)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
3D tissue models, high-throughput drug screening, preclinical drug testing, tissue engineering, disease models
MeSH terms
Animals, Drug Evaluation, Preclinical, Humans, Organ Culture Techniques, Tissue Engineering, Biomimetics, Nanotechnology, High-Throughput Screening Assays

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review